Latuda (lurasidone) is an atypical antipsychotic, a newer class of antipsychotic medications sometimes called “second-generation.” The FDA first approved it in 2010 for schizophrenia in adults, and its approved uses have expanded since then. Despite the name “antipsychotic,” Latuda is widely prescribed for bipolar depression as well, which is worth understanding if you or someone you know has been prescribed it for mood-related symptoms rather than psychosis.
What Latuda Is Approved to Treat
Latuda has three distinct FDA-approved uses:
- Schizophrenia in adults and adolescents aged 13 to 17
- Bipolar I depression as a standalone treatment in adults and children aged 10 to 17
- Bipolar I depression as an add-on to lithium or valproate in adults
It’s not approved for general depression (major depressive disorder without bipolar disorder), anxiety, or bipolar mania. Its role is specifically in treating the depressive episodes that occur within bipolar I disorder. This distinction matters because many people hear “antipsychotic” and assume the medication is only for psychosis, when in reality Latuda is prescribed just as often for mood symptoms.
How It Works
Like other atypical antipsychotics, Latuda works by influencing dopamine and serotonin activity in the brain. It blocks certain dopamine receptors, which helps reduce psychotic symptoms like hallucinations and disorganized thinking. It also acts on serotonin receptors in ways that appear to improve mood and may contribute to fewer movement-related side effects compared to older antipsychotics. This dual action on both dopamine and serotonin pathways is what distinguishes “atypical” antipsychotics from the older “typical” generation.
How Well It Works for Bipolar Depression
Clinical trial data gives a clearer picture of what to expect. In a six-week monotherapy trial, about 51 to 53% of patients with bipolar I depression had a meaningful response to Latuda, compared to 30% on placebo. Remission rates, meaning depression symptoms dropped to minimal levels, reached 40 to 42% on Latuda versus 25% on placebo. Interestingly, lower and higher dose ranges performed almost identically, suggesting more isn’t necessarily better.
When added to a mood stabilizer like lithium or valproate, Latuda improved response rates to 57% versus 42% on placebo. Patients who took Latuda alongside a mood stabilizer also reached remission faster, at a median of 35 days compared to 43 days for those on placebo plus a mood stabilizer.
Weight Gain and Metabolic Effects
One of Latuda’s most notable advantages over other antipsychotics is its relatively low impact on weight. In a Phase 3 trial, only 5.9% of patients on Latuda gained 7% or more of their body weight, compared to 34.4% of patients on olanzapine (Zyprexa) and 7.0% on placebo. Over 12 months of longer-term data, Latuda was associated with an average weight change of negative 0.4 kg, essentially weight-neutral. By comparison, risperidone was linked to a 2.6 kg gain and quetiapine extended release to a 1.2 kg gain over the same period.
For people who are concerned about the metabolic effects that come with many antipsychotics, including weight gain, blood sugar changes, and cholesterol increases, this profile is a significant practical consideration.
Movement-Related Side Effects
Latuda does carry a notable risk of akathisia, a restless, uncomfortable urge to move that can feel like inner agitation. A meta-analysis of placebo-controlled trials found that roughly 1 in 10 patients taking Latuda experienced drug-related akathisia. This was higher than rates seen with some other atypical antipsychotics like quetiapine, though lower than ziprasidone in at least one head-to-head comparison.
The risk of other movement-related side effects is also elevated. Dystonia (involuntary muscle contractions) and parkinsonism-like symptoms (stiffness, tremor, slowed movement) occurred at higher rates than placebo. These effects are generally manageable and often dose-related, but they’re worth knowing about. If you experience restlessness or stiffness after starting Latuda, that’s a recognized side effect rather than something unrelated.
The Food Requirement
Latuda has an unusual practical requirement: it must be taken with food containing at least 350 calories. This isn’t optional advice. Taking Latuda on an empty stomach substantially reduces how much of the drug your body absorbs, which can make it less effective. The good news is that the type of food doesn’t matter much. Absorption was consistent whether the meal was 350 or 1,000 calories and regardless of fat content. A moderate-sized meal or substantial snack is enough.
This requirement can be a practical challenge for people who take their medication at bedtime and don’t typically eat late, or for those whose appetite is suppressed by depression. Planning a consistent mealtime around your dose helps ensure the medication works as intended.
How Latuda Compares to Other Antipsychotics
Among atypical antipsychotics, Latuda occupies a specific niche. It causes significantly less weight gain than olanzapine and less than risperidone or quetiapine. It also tends to cause less sedation than quetiapine, which is heavily sedating for many people. On the other hand, its akathisia rates are higher than some alternatives, and the food requirement adds a layer of planning that other medications don’t need.
Latuda is not approved for bipolar mania or as a general mood stabilizer. If your provider has prescribed it, the target is most likely either schizophrenia symptoms or the depressive side of bipolar I disorder. Other atypical antipsychotics like quetiapine and olanzapine-fluoxetine combinations are also used for bipolar depression, so Latuda is one of several options in this space, each with different tradeoffs around weight, sedation, and movement side effects.